TY - JOUR
T1 - Myocarditis in Athletes Recovering from COVID-19: A Systematic Review and Meta-Analysis
AU - Modica, Gloria
AU - Bianco, Massimiliano
AU - Sollazzo, Fabrizio
AU - Di Murro, Emanuela
AU - Monti, Riccardo
AU - Cammarano, Michela
AU - Morra, Lorenzo
AU - Nifosi', Francesco Maria
AU - Gervasi, Salvatore Francesco
AU - Gravina, Ester Manes
AU - Zeppilli, Paolo
AU - Palmieri, Vincenzo
PY - 2022
Y1 - 2022
N2 - Background: To assess the event rates of myocarditis detected by Cardiac Magnetic Resonance (CMR) in athletes who recovered from COVID-19. Methods: A systematic literature search was performed to identify studies reporting abnormal CMR findings in athletes who recovered from COVID-19. Secondary analyses were performed considering increased serum high sensitivity troponin (hs-Tn) levels and electrocardiographic (ECG) and echocardiographic (ECHO) abnormalities. Results: In total, 7988 athletes from 15 studies were included in the analysis. The pooled event rate of myocarditis was 1% (CI 1-2%), reaching 4% in the sub-group analysis. In addition, heterogeneity was observed (I2 43.8%). The pooled event rates of elevated serum hs-Tn levels, abnormal ECG and ECHO findings were 2% (CI 1-5%), 3% (CI 1-10%) and 2% (CI 1-6%), respectively. ECG, ECHO and serum hs-Tn level abnormalities did not show any correlation with myocarditis. Conclusions: The prevalence of COVID-19-related myocarditis in the athletic population ranges from 1 to 4%. Even if the event rate is quite low, current screening protocols are helpful tools for a safe return to play to properly address CMR studies. Trial registration: the study protocol was registered in the PROSPERO database (registration number: CRD42022300819).
AB - Background: To assess the event rates of myocarditis detected by Cardiac Magnetic Resonance (CMR) in athletes who recovered from COVID-19. Methods: A systematic literature search was performed to identify studies reporting abnormal CMR findings in athletes who recovered from COVID-19. Secondary analyses were performed considering increased serum high sensitivity troponin (hs-Tn) levels and electrocardiographic (ECG) and echocardiographic (ECHO) abnormalities. Results: In total, 7988 athletes from 15 studies were included in the analysis. The pooled event rate of myocarditis was 1% (CI 1-2%), reaching 4% in the sub-group analysis. In addition, heterogeneity was observed (I2 43.8%). The pooled event rates of elevated serum hs-Tn levels, abnormal ECG and ECHO findings were 2% (CI 1-5%), 3% (CI 1-10%) and 2% (CI 1-6%), respectively. ECG, ECHO and serum hs-Tn level abnormalities did not show any correlation with myocarditis. Conclusions: The prevalence of COVID-19-related myocarditis in the athletic population ranges from 1 to 4%. Even if the event rate is quite low, current screening protocols are helpful tools for a safe return to play to properly address CMR studies. Trial registration: the study protocol was registered in the PROSPERO database (registration number: CRD42022300819).
KW - COVID-19
KW - athletes
KW - cardiac magnetic resonance
KW - myocarditis
KW - physical activity
KW - COVID-19
KW - athletes
KW - cardiac magnetic resonance
KW - myocarditis
KW - physical activity
UR - http://hdl.handle.net/10807/229490
U2 - 10.3390/ijerph19074279
DO - 10.3390/ijerph19074279
M3 - Article
SN - 1660-4601
VL - 19
SP - 4279
EP - 4290
JO - International Journal of Environmental Research and Public Health
JF - International Journal of Environmental Research and Public Health
ER -